Equities research analysts expect PetMed Express, Inc. (NASDAQ:PETS) to post sales of $62.86 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for PetMed Express’ earnings, with the highest sales estimate coming in at $65.30 million and the lowest estimate coming in at $58.80 million. PetMed Express posted sales of $60.79 million in the same quarter last year, which would indicate a positive year over year growth rate of 3.4%. The company is scheduled to announce its next earnings results on Monday, October 23rd.

On average, analysts expect that PetMed Express will report full-year sales of $62.86 million for the current year, with estimates ranging from $260.30 million to $268.24 million. For the next financial year, analysts expect that the firm will report sales of $276.56 million per share, with estimates ranging from $269.70 million to $283.42 million. Zacks’ sales averages are an average based on a survey of analysts that cover PetMed Express.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings data on Monday, July 24th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.38 by $0.07. PetMed Express had a return on equity of 28.67% and a net margin of 10.34%. The firm had revenue of $79.66 million for the quarter, compared to the consensus estimate of $77.32 million. During the same quarter last year, the company earned $0.32 earnings per share. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year.

PETS has been the topic of a number of recent analyst reports. Sidoti upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 price target on the stock in a research report on Thursday, August 24th. BidaskClub downgraded PetMed Express from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 22nd. Northcoast Research upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 price target on the stock in a research report on Monday, July 24th. Craig Hallum downgraded PetMed Express from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, Noble Financial reiterated a “hold” rating on shares of PetMed Express in a research report on Wednesday, July 26th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $44.75.

Shares of PetMed Express (NASDAQ:PETS) opened at 34.34 on Tuesday. The company’s 50-day moving average price is $40.97 and its 200 day moving average price is $33.60. PetMed Express has a 52 week low of $18.90 and a 52 week high of $50.90. The company has a market cap of $696.83 million, a P/E ratio of 26.42 and a beta of 1.03.

COPYRIGHT VIOLATION WARNING: “$62.86 Million in Sales Expected for PetMed Express, Inc. (PETS) This Quarter” was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/26/62-86-million-in-sales-expected-for-petmed-express-inc-pets-this-quarter.html.

In other PetMed Express news, Director Ronald J. Korn sold 5,000 shares of the stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $48.18, for a total transaction of $240,900.00. Following the completion of the transaction, the director now owns 67,333 shares of the company’s stock, valued at $3,244,103.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert C. Schweitzer sold 2,500 shares of the stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $49.18, for a total value of $122,950.00. Following the transaction, the director now directly owns 88,834 shares of the company’s stock, valued at approximately $4,368,856.12. The disclosure for this sale can be found here. Insiders have sold 19,333 shares of company stock valued at $949,730 in the last three months. Insiders own 4.00% of the company’s stock.

Several institutional investors have recently made changes to their positions in the business. Pinebridge Investments L.P. raised its holdings in shares of PetMed Express by 1.0% during the second quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock valued at $110,000 after acquiring an additional 27 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of PetMed Express by 0.9% during the first quarter. Arizona State Retirement System now owns 10,667 shares of the company’s stock valued at $215,000 after acquiring an additional 100 shares during the last quarter. Texas Permanent School Fund raised its holdings in shares of PetMed Express by 0.8% during the second quarter. Texas Permanent School Fund now owns 14,986 shares of the company’s stock valued at $608,000 after acquiring an additional 125 shares during the last quarter. Advisor Group Inc. raised its holdings in shares of PetMed Express by 0.7% during the second quarter. Advisor Group Inc. now owns 24,844 shares of the company’s stock valued at $1,009,000 after acquiring an additional 179 shares during the last quarter. Finally, QS Investors LLC raised its holdings in shares of PetMed Express by 4.0% during the second quarter. QS Investors LLC now owns 9,324 shares of the company’s stock valued at $379,000 after acquiring an additional 356 shares during the last quarter. 78.91% of the stock is owned by institutional investors and hedge funds.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Get a free copy of the Zacks research report on PetMed Express (PETS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.